SCL Science

SCL Science Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of SCL Science (246960.KQ) as of Nov 18, 2026 is -8.18. In the previous year, Cash Conversion Cycle (CCC) was 283.94 — a change of -102.88% (lower).

Cash Conversion Cycle

-8.18

YoY

-102.88%

Last updated:

Cash Conversion Cycle (CCC) of SCL Science is 2025 -8.18 . Cash Conversion Cycle (CCC) of SCL Science was 2024 283.94 . It decreases by -102.88% lower compared to the previous year.

The SCL Science Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
377.66 KRW
Jan 1, 2019
279.26 KRW
Jan 1, 2020
307.16 KRW
Jan 1, 2021
254.29 KRW
Jan 1, 2022
477.93 KRW
Jan 1, 2023
269.70 KRW
Jan 1, 2024
283.94 KRW
Jan 1, 2025
-8.18 KRW
The SCL Science Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-8.18-102.88%
283.94+5.28%
269.70-43.57%
477.93+87.94%
254.29-17.21%
307.16+9.99%
279.26-26.06%
377.66+0.04%
377.51+71.06%
220.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Cash Conversion Cycle (CCC) of SCL Science is -8.18 in 2025.

Cash Conversion Cycle (CCC) of SCL Science changed from 283.94 to -8.18, representing a -102.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) SCL Science since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s SCL Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SCL Science

All Key Metrics — SCL Science